Qiagen N.V. (NYSE:QGEN) Bank of America Global Healthcare Conference 2025 September 25, 2025 5:45 AM EDT
Company Participants
John Gilardi – VP & Head of Corporate Communications
Conference Call Participants
Michael Ryskin – BofA Securities, Research Division
Presentation
Michael Ryskin
BofA Securities, Research Division
Thanks for joining us. My name is Mike Ryskin. I’m on the Bank of America Life Science Tools and Diagnostics team based out of New York. We’re excited for our next session. We’re joined by John Gilardi, Head of Investor Relations for QIAGEN. John, thanks so much for being here.
John Gilardi
VP & Head of Corporate Communications
Thank you for the invitation.
Question-and-Answer Session
Michael Ryskin
BofA Securities, Research Division
Format will be a fireside chat, but feel free to raise your hand, and we’ll let you jump in.
John, maybe to kick things off a little bit. We’re about 3/4 of the way through the year. Can we take a step back and sort of review how the year has played out so far relative to your initial expectations? Maybe what have been the biggest surprises, both upside or downside?
John Gilardi
VP & Head of Corporate Communications
Well, I think this year is proving the value of our business in that we are serving the continuum from life sciences through to diagnostics. More than 80% of the products in our portfolio, we are able to sell to life science labs, to diagnostic labs. And what we’re seeing this year is that 1 year, life sciences will do better than diagnostics, 1 year diagnostics will do better than life sciences.
And that’s the way this year is playing out. We’re seeing very strong trends in diagnostics, especially with our QuantiFERON test for latent TB detection, doing very well, continuing solid growth, approaching $500 million of sales this year. We’re seeing very
#Qiagen #N.V #QGEN #Presents #Bank #America #Global #Healthcare #Conference #Transcript